Spread the loveModerna is back at the public trough with another experimental mRNA vaccine, this time targeting the Bundibugyo strain of Ebola. There is no approved vaccine specifically targeting Bundibugyo Ebola, but Moderna is not financing this humanitarian venture alone. If it succeeds, Moderna gains another proprietary vaccine and governments or international organizations will purchase the doses. Moderna and Pfizer-BioNTech were once projected to generate between $93.2 billion and $124 billion in combined vaccine sales during 2022. It has pursued mRNA products for seasonal flu, bird flu, RSV, norovirus, Epstein-Barr virus, cytomegalovirus, and now Ebola.